Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, Yesterday

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

ENTERPRET: Vedolizumab found to have positive exposure–response pattern in UC

Jairia Dela Cruz
20 Feb 2020

Among patients with ulcerative colitis (UC), vedolizumab serum concentrations in the fifth week after treatment initiation appear to have been higher in those who do vs do not show response in the sixth week, according to interim data from ENTERPRET study presented at the 2020 Crohn’s and Colitis Congress (CCC).

Pivotal trial data provided evidence to support an association between drug exposure and clinical remission during induction therapy at week 6. Specifically, the majority of UC patients who did not respond to vedolizumab had drug exposure levels <40 μg/mL, and a drug clearance of >0.14 L/d correlated with poorer efficacy outcomes. [Aliment Pharmacol Ther 2019;49:408-418]

Meanwhile, the ongoing randomized controlled trial ENTERPRET aims to assess whether dose escalation starting at week 6 in nonresponders with high vedolizumab clearance (level <50 µg/mL) at week 5 leads to better outcomes at week 30.

The current interim analysis evaluated baseline predictors of response at week 6 and involved 117 adult patients (mean age, 41.2 years; 40.2 percent female) with moderately to severely active UC treated with intravenous vedolizumab 300 mg on day 1 and week 2. Serum drug concentration at week 5 was measured.

At week 6, 55 patients responded to treatment while 57 did not. Clinical response was defined as a reduction in partial Mayo score of ≥2 points and ≥25-percent reduction from baseline, with a parallel decrease in rectal bleeding subscore or absolute rectal bleeding score of ≤1 point. [CCC 2020, abstract P065]

With respect to baseline characteristics, responders had shorter disease duration compared with nonresponders (mean, 7.1 vs 9.5 years), with fewer responders having disease duration of ≥7 years (38.2 percent vs 47.4 percent). The proportion of patients who were naïve to treatment with antitumour necrosis factor among responders was higher than among nonresponders (67.3 percent vs 52.6 percent).

More nonresponders than responders had severely active disease (Mayo endoscopic subscore, 3; 49.1 percent vs 36.4 percent), as well as higher stool frequency (Mayo subscore, 3; 63.2 percent vs 49.1 percent). Finally, a higher number of responders had more severe rectal bleeding scores (Mayo subscore, 2–3; 63.6 percent vs 45.6 percent of nonresponders).

At week 6, partial Mayo score from baseline decreased to a greater magnitude in responders vs nonresponders (mean, –4.2 vs –0.2). Week-5 vedolizumab serum concentrations were numerically higher in the former (mean, 40.3 vs 31.5 µg/mL). No unexpected treatment-emergent adverse events were recorded in either group.

“Although current results are consistent with the hypothesis that lower response to vedolizumab at week 6 correlates with lower drug exposure, we await the final results of ENTERPRET to better understand the exposure-response relationship of [the drug],” the investigators said.

A gut-selective antibody that binds specifically to integrin α4β7, vedolizumab is approved for treatment of adults with moderate-to-severe UC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, Yesterday

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.